The GHRH receptor is expressed in the somatotroph cell of the anterior pituitary, where it functions to mediate GHRH-stimulated GH release. To study pituitary and somatotroph cell-specific expression of this gene, a transgenic mouse model and complementary cell culture experiments were developed. The activity of the 1.6-kb proximal rat GHRH receptor promoter was examined in vivo by generating transgenic mice with the promoter directing expression of a luciferase reporter. The promoter directs tissue-specific expression; luciferase is highly expressed in the pituitary but absent from 14 other tissues. Immunocytochemistry experiments show that transgene expression is targeted to GH-expressing somatotroph cells. The transgene is 5-fold more highly expressed in males than females, and there is an increase in transgene expression leading up to the onset of puberty. The 1.6-kb promoter was further examined in cell culture experiments, which revealed that the promoter is selectively activated in pituitary cells and that promoter-reporter expression in nonpituitary cells can be enhanced by the pituitary-specific transcription factor Pit-1. EMSAs identified 10 short regions that specifically bind Pit-1 with highly variable relative affinities. The highest affinity site was previously identified and is required for Pit-1 activation of the promoter. T HE ANTERIOR PITUITARY gland comprises five cell types that are defined by the hormones they secrete. Development of the anterior pituitary is characterized by a series of inductive signals from the neural ectoderm of the ventral diencephalon (1-5) that stimulates the growth and differentiation of the anterior pituitary primordium, Rathke's pouch, around embryonic d 8.5 in the mouse (6-8). Once established, Rathke's pouch creates an ectodermal boundary that allows subsequent signaling gradients (9), which stimulate the expression of transcription factors in overlapping patterns (9-14), leading to the differentiation of the various pituitary cell types, which are specified by embryonic d 17.5 (15). An opposing ventrodorsal gradient of BMP2 and FGF8 (9, 16) is required to differentiate the ventral cell phenotypes from the dorsal cell phenotypes, and reciprocal gradients of Pit-1 and GATA-2 are involved in the differentiation of the four most caudal cell lineages, gonadotrophs, thyrotrophs, lactotrophs, and somatotrophs (14).
T HE ANTERIOR PITUITARY gland comprises five cell types that are defined by the hormones they secrete. Development of the anterior pituitary is characterized by a series of inductive signals from the neural ectoderm of the ventral diencephalon (1) (2) (3) (4) (5) that stimulates the growth and differentiation of the anterior pituitary primordium, Rathke's pouch, around embryonic d 8.5 in the mouse (6) (7) (8) . Once established, Rathke's pouch creates an ectodermal boundary that allows subsequent signaling gradients (9) , which stimulate the expression of transcription factors in overlapping patterns (9) (10) (11) (12) (13) (14) , leading to the differentiation of the various pituitary cell types, which are specified by embryonic d 17.5 (15) . An opposing ventrodorsal gradient of BMP2 and FGF8 (9, 16 ) is required to differentiate the ventral cell phenotypes from the dorsal cell phenotypes, and reciprocal gradients of Pit-1 and GATA-2 are involved in the differentiation of the four most caudal cell lineages, gonadotrophs, thyrotrophs, lactotrophs, and somatotrophs (14) .
The pituitary somatotroph cell, which secretes GH, integrates signals from the hypothalamus to regulate GH release. In vertebrates GH promotes proliferation (17) (18) (19) (20) (21) , differentiation (22) (23) (24) (25) (26) , and metabolism (27) (28) (29) (30) of target tissues throughout the body. GHRH, a hypothalamic peptide hormone, is the primary stimulus for GH synthesis (31, 32) and secretion (32) (33) (34) and acts by binding to its receptor on the surface of pituitary somatotroph cells. The GHRH receptor is a seven-transmembrane G protein-coupled receptor that is closely related to the receptors for the related peptide hormones, vasoactive intestinal polypeptide, secretin, and glucagon (35) .
Pituitary somatotroph cells and lactotroph cells, which secrete prolactin, differentiate from a common precursor cell. Terminally differentiated somatotroph cells express the GHRH receptor and respond to GHRH stimulation (36) . Therefore, discovery of how the GHRH receptor gene is regulated is expected to lead to a better understanding of what factors are involved in the differentiation of the somatotroph cell lineage from the four other cell types of the anterior pituitary gland. The GHRH receptor gene is known to be regulated by several factors, including glucocorticoids (37) (38) (39) (40) (41) , thyroid hormone (41) , retinoic acid (41) , GHRH (36, 42) , and the pituitary-specific transcription factor Pit-1 (38, (43) (44) (45) , but the mechanism of regulation has not been elucidated for most of these factors.
The transcription factors Prop-1 (11, 12) and Pit-1 are required for the differentiation of the thyrotroph (46) , lactotroph (47) , and somatotroph (48) cell lineages from a common pituitary precursor. Pit-1 is a pituitary-specific POU homeodomain transcription factor (49, 50) that is involved in the transcriptional activation of the GH gene in somatotroph cells and of the prolactin gene in lactotroph cells (51) (52) (53) . Previous work from our laboratory and others has shown that Pit-1 also leads to activation of the GHRH receptor promoter (38, 43, 44) . Further indicative of the important role Pit-1 plays in stimulating GHRH receptor expression, a mutation in a human GHRH receptor Pit-1 binding site results in decreased expression of the receptor in a patient exhibiting GH deficiency (45) . Pit-1 has recently been shown to be required for glucocorticoid regulation of the rat (r) GHRH receptor (54) , suggesting that cooperation between Pit-1 and other factors may lead to differential cell-specific gene regulation.
Mutations in the GHRH receptor in human (55) (56) (57) (58) and in animal models (59) (60) (61) lead to dwarfism and pituitary hypoplasia due to lack of somatotrophs, indicating an integral role for the receptor in regulation of appropriate GH levels. Given the importance of the GHRH receptor in mediating the neuroendocrine pathway regulating GH levels, understanding regulation of the GHRH receptor gene itself is important.
The current study seeks to determine what promoter elements are required to direct tissue-and cellspecific expression of the GHRH receptor gene. Using transgenic mice and cell culture systems, we show that the 1.6-kb promoter is sufficient to direct tissueand cell-specific expression in vivo and that the cell specificity is mimicked in vitro. In further examination of elements within the 1.6-kb promoter, we mapped 10 Pit-1 binding sites and show that five of these contribute to Pit-1-regulated expression of the GHRH receptor. Of these, the greatest contribution to Pit-1-activated expression of the gene is achieved by two well-conserved, high-affinity sites, Ϫ888 to Ϫ857 and ϩ129 to ϩ164.
RESULTS

Pituitary-Specific Expression of the Luciferase Transgene
Two independent lines of transgenic mice were generated in which the 1.6-kb GHRH receptor promoter directs a luciferase reporter. Luciferase assays were performed on pituitaries taken from normal littermate and transgenic mice for each line. Luciferase expression is significant in transgenic pituitaries in each line (Fig. 1A) . Transgenic mice in line 2 show significantly higher transgene expression than those in line 1 (Fig.  1A) . Due to the robust transgene expression level in the pituitary of transgenic mice in line 2, this line was used for further analyses and data from line 2 are reported here.
To determine whether the 1.6-kb promoter is sufficient to direct tissue-specific expression of the GHRH receptor, multiple endocrine and nonendocrine tissues from both normal littermate and transgenic mice were examined for luciferase expression. In addition to pituitary the tissues tested include medial-basal hypothalamus, cerebellum, pancreas, cerebral cortex, testes/ovary, heart, lung, adrenal gland, kidney, spleen, muscle, skin, thymus, and liver. Only in the pituitary gland were relative light units significantly higher for the transgenic sample compared with the normal littermate sample (Fig. 1B) .
Transgene Expression Is Targeted to Somatotroph Cells
To determine whether the transgene is restricted to somatotroph cells, immunocytochemistry was performed on dispersed pituitary cells from transgenic and normal littermate mice. In control samples where the primary antibodies are omitted, no fluorescence is observed (Fig. 2, A-H ). An antibody to GH was used to localize somatotroph cells. A luciferase antibody was used to examine transgene localization. The GH antibody shows that somatotroph cells in both normal littermate (Fig. 2J ) and transgenic ( Fig. 2N ) pituitaries occur at equivalent numbers. As expected, the luciferase antibody shows luciferase expression in pituitary cells of only the transgenic mice (Fig. 2O) .
Overlays of the channels detecting GH and luciferase antibodies reveal that the two antibodies colocalize in the transgenic pituitary (Fig. 2P) , indicating that the luciferase transgene is expressed in somatotroph cells of the anterior pituitary gland. In immunocytochemistry experiments, all somatotroph cells express the luciferase transgene (n Ͼ 1000 cells). In fewer than 5% of cells expressing the transgene, GH is not detected (n Ͼ1000 cells). This small number of cells is not likely significant enough to represent an entire population of an additional pituitary cell type. Thus, we conclude that transgene expression is somatotroph cell specific.
Transgene Expression Is Sexually Dimorphic and Regulated during Postnatal Development
Transgene expression was examined in males compared with females to determine whether sexual dimorphism in transgene expression occurs. Transgene expression levels are strikingly higher in transgenic pituitaries from males than from females, with a difference of more than 5-fold (Fig. 3) .
To determine whether the 1.6-kb promoter regulates changes in receptor expression during postnatal development and aging, luciferase assays were performed on pituitaries from transgenic animals ranging from d 1 postnatal through 1 yr of age (Fig. 4) . Similar to reports on expression of the endogenous GHRH receptor (62) , there is a significant increase in transgene expression in the time leading up to puberty (30-35 d in the male mouse) (Fig. 4) . In contrast to the endogenous receptor, transgene expression levels do not consistently decrease as the animal ages (Fig. 4) .
Cell-Specific and Pit-1-Activated Expression of the rGHRH Receptor Promoter in Cell Culture
Having established the 1.6-kb promoter as sufficient in vivo to direct tissue-and cell-specific expression, we further examined regulation of this promoter in cell culture experiments. A rGHRH receptor promoter-luciferase reporter construct (rGHRH receptor Ϫ1673) is not expressed in a nonpituitary cell line, HeLa T4 cells, but is highly expressed in a GH-secreting pituitary cell line, GH3 cells (Fig. 5) . In nonpituitary HeLa cells, coexpression of Pit-1 leads to significant activation of the rGHRH receptor Ϫ1673 construct. Because Pit-1 is expressed in GH3 cells, Pit-1 coexpression in transfections of these cells leads to little or no further activation of the GHRH receptor promoter reporter (Fig.  5) . Pit-1-activated levels of this promoter in HeLa cells are 8-fold lower than basal expression levels in GH3 cells, indicating that factors in addition to Pit-1 are required for full activation of the promoter (Fig. 5) . Given the ability of Pit-1 to stimulate expression of the promoter in a nonpituitary cell line, we focused on identifying functional binding sites for this transcription factor, which appears to be a critical determinant of GHRH receptor gene expression.
Pit-1 Binding to the 1.6-kb rGHRH Receptor Promoter
To determine whether Pit-1 binds to the rGHRH receptor promoter and where it binds, EMSAs were performed using overlapping probes spanning the proximal promoter. A Western blot shows Pit-1 expression in nuclear extracts from cells transfected with the Pit-1 construct, which were used in the binding reactions, and no expression in nuclear extracts from mock-transfected cells, which were used as a negative control (Fig. 6A) . DNA probes are shown schematically in Fig. 6C . In the rat, four transcriptional start sites for the GHRH receptor gene have been identified (43) ; these are depicted as arrows in the schematic (Fig. 6C) . We refer to the 5Ј-most of these start sites as "ϩ1." Only the 3Ј-most probe was negative for Pit-1 binding (Fig. 6B) . Pit-1 binds to each of the other seven probes, as nuclear extracts from cells overexpressing Pit-1 shift the mobility of the promoter probes (Fig. 6B,  lanes 3 ). An unlabeled oligonucleotide composed of a consensus Pit-1 binding site competes away Pit-1 binding (Fig. 6B, lanes 4) , but an unlabeled oligonucleotide with a mutated Pit-1 binding site has no effect on binding (Fig. 6B, lanes 5 ). Incubation of the nuclear extracts with an antibody to Pit-1 supershifts the Pit-1 binding band (Fig. 6B, lanes 6 whereas normal serum does not affect binding (Fig.  6B , lanes 7). Pit-1 binding to the Ϫ1673 to Ϫ1323 region is less definitive than for the other six regions, because normal serum, in addition to the Pit-1 antibody, supershifted the Pit-1 band, although this band has a distinct mobility from the Pit-1 antibody shift.
Pit-1 Specifically Binds 10 Sites in the 1.6-kb rGHRH Receptor Promoter
To determine short DNA regions that bind Pit-1 specifically, sequential sets of overlapping smaller oligonucleotide probes were generated to each region mapped in Fig. 6 and used in EMSAs. In a previous report, four putative Pit-1 binding sites in the 1.6-kb promoter were identified computationally (43) . The binding experiments show that, in fact, 10 short regions of the 1.6-kb rGHRH receptor promoter bind Pit-1 specifically (Fig. 7, lanes 3 ). The binding of Pit-1 to these probes is competed by an unlabeled Pit-1 site oligonucleotide (Fig. 7, lanes 4) , not competed by a mutated Pit-1 site oligonucleotide (Fig. 7 , lanes 5), supershifted by incubation with an antibody to Pit-1 (Fig. 7 , lanes 6), and unaffected by incubation with normal rabbit serum (Fig. 7, lanes 7) . Not surprisingly, several of these promoter probes also bind nuclear proteins from mock-transfected cells (Fig. 7 , lanes 2). For most of these, the band representing binding of other (non-Pit-1) proteins migrates at a different size than Pit-1. For others (Ϫ348 to Ϫ313 and Ϫ81 to Ϫ46) the band migrates at a similar size, but the band intensity is much greater in the Pit-1 nuclear extract lane. Pit-1-specific binding was determined by competition with a cold Pit-1 consensus oligonucleotide (but not with a mutated version of it) and supershift with Pit-1 antibody. No defined binding sites were detectable within the Ϫ1673 to Ϫ1323 region, possibly indicative of the existence of multiple weak-affinity sites within this region, or lack of specificity of binding, as discussed for Fig. 6 .
When key nucleotides are mutated from A/T to G (Table 1) , Pit-1 binding to these sequences is completely abolished (Fig. 7 , Mut panels). Because no strong consensus Pit-1 binding site exists, it was not possible to predetermine a single target for effective mutation in these probes. Instead, several nucleotides were mutated within the presumed core sequence of each Pit-1 probe ( Table 1 ).
The rGHRH Receptor Promoter Pit-1 Binding Sites Exhibit Varying Affinities for Pit-1
The 10 Pit-1 binding sites were examined more closely to determine which site or sites might be important to Pit-1 activation of the GHRH receptor gene. Because the observation was made in initial experiments that different sites seem to bind Pit-1 with different affinities, we examined relative binding affinities of the sites. EMSAs were performed by incubating increasing amounts of Pit-1 nuclear extracts, ranging from 0 M to 2000 M, with each of the labeled probes (Fig. 8, A and B). Average relative affinities were compared with the affinity of a known Pit-1 binding sequence (63) , which is referred to as the Pit-1 consensus sequence (Fig. 8 ). Relative affinities for the 10 sites are highly variable, with EC 50 values ranging from 300 M for the ϩ129 to ϩ164 site to greater than 2000 M for six of the sites (Fig. 8C ). Affinity ranks are listed for comparison (Fig. 8C) .
Conservation of Pit-1 Binding Sequences across Multiple Species
To examine evolutionary conservation of the Pit-1 binding sequences, the rat promoter sequence was aligned to the genomic sequences of other species (data not shown). As might be expected, there was strong homology between rat and mouse that was less robust in other species (human, chimpanzee, dog, and rhesus monkey). A percent conservation and conservation raking was calculated for each of the sites, and the ranks are shown (Fig. 8C ). There is some correlation between relative affinities and amount of conservation of the sequences. For example, the most highly conserved sequence, ϩ129 to ϩ164, is the site with the highest relative affinity for Pit-1, and the least well-conserved sequence, Ϫ348 to Ϫ313, is among the lowest affinity sites (Fig. 8C) .
Two human GHRH receptor promoter Pit-1 binding sites have been identified (44) . The more 5Ј of these human sites, which contributes most to Pit-1 activation of the human GHRH receptor, is highly conserved and corresponds to the high-affinity ϩ129 to ϩ164 rat site, indicating a possible functional importance for this site in regulating the rGHRH receptor gene.
Functional Analysis of Pit-1 Binding Sites
Because Pit-1 does not further activate expression of the 1.6-kb rGHRH receptor construct in GH3 cells, we performed experiments in HeLa cells to examine the contribution of Pit-1 to regulation of the receptor gene and compared these data to basal reporter expression in GH3 cells.
In HeLa cells, Pit-1 significantly activates a series of 5Ј-deletion constructs up to the rGHRH receptor Ϫ131 construct, which still contains the high-affinity, highly conserved ϩ129 to ϩ164 site (Fig. 9A ). When this site is removed, in the rGHRH receptor ϩ148 construct, Pit-1 activation is lost (Fig. 9A) . Because basal expression of the 5Ј-deletion constructs varied, we also examined fold increase in reporter expression with Pit-1 cotransfection for each of the promoter deletion constructs. This analysis shows that Pit-1 significantly increases promoter activity for each construct except the shortest, which lacks Pit-1 binding sites (Fig. 9B) . Pit-1 coexpression has the greatest effect on the full-length Ϫ1673 construct, suggesting that multiple binding sites are necessary for full Pit-1 responsiveness of this gene (Fig. 9B) .
To further examine the individual contributions of the identified Pit-1 binding sites, functional analysis of the Pit-1 binding site mutations was performed. Five of the Pit-1 binding sites exhibit significantly reduced Pit-1-activated expression when mutated (Fig. 9C) . The most dramatic loss of Pit-1 activation is observed when either the Ϫ888 to Ϫ857 or ϩ129 to ϩ164 site is mutated. Because changes in basal expression were apparent in these experiments, fold increase in reporter expression with Pit-1 coexpression was examined for these mutation constructs. The fold increase is significant for each of the mutations except the ϩ129 to ϩ164 site (Fig. 9D) , supporting that Pit-1 binding to this site is essential for activating the rGHRH receptor promoter.
GHRH receptor promoter deletion and mutation constructs were also examined in pituitary GH3 cells. Interestingly, the pattern of basal reporter expression for the promoter 5Ј-deletion constructs follows the pattern of Pit-1-activated reporter expression seen in HeLa cells (Fig. 10A) . Mutation of seven of the 10 Pit-1 binding sites results in significantly reduced basal expression in GH3 cells (Fig. 10B) . These sites include those that exhibit reduced Pit-1-activated expression when mutated in HeLa cells, in addition to two others. As in HeLa cells, no activation of the reporter occurs when Pit-1 is unable to bind the critical ϩ129 to ϩ164 site (Fig. 10B) .
DISCUSSION
The primary goal of this study was to expand our understanding of pituitary-and somatotroph cell- specific expression of the GHRH receptor gene. Examination of transcriptional regulation of this gene, which is expressed early in terminally differentiated somatotroph cells, will lead to a better understanding of the events leading to cell specification of the somatotroph lineage. The approach we took was to characterize regulation of the rGHRH receptor promoter in vivo, in an attempt to define elements required to direct tissue-and cell-specific expression, and to further study regulation of the defined promoter in a cell culture system. Previous cell culture experiments have shown that the 1.6-kb rGHRH receptor promoter was able to direct expression of reporter constructs in a pituitary cell line (43) . To determine whether this part of the promoter was sufficient in vivo to direct tissue-and cellspecific expression of the receptor, transgenic mice were generated. The transgene contains the Ϫ1673 to ϩ289 fragment cloned upstream of a luciferase reporter. The data show that the transgene is specifically expressed in the pituitary, is targeted to somatotroph cells, and is expressed in a sexually dimorphic and age-dependent manner.
Just as endogenous GHRH receptor expression is largely restricted to the pituitary (35), transgene expression is specific to the pituitary in transgenic mice, suggesting that tissue specificity of expression is driven by elements within the 1.6-kb promoter. Interestingly, no transgene expression is observed in the kidney, where an alternative GHRH receptor mRNA is expressed in the rat (35) . Studies in our group (Zheng, J., and K. Mayo, unpublished) suggest that this mRNA is transcribed from a different promoter. A report has suggested that endogenous GHRH receptor expres- sion is restricted to somatotroph cells of the anterior pituitary gland (64) in experiments in which cell type was morphologically determined. Although a small percentage of nonsomatotroph cells express the GHRH receptor promoter transgene, all somatotroph cells, defined by GH-positive immunocytochemistry, express the transgene. The results support the finding that endogenous GHRH receptor expression is somatotroph specific and suggest that the cell-specific expression is determined by elements in the 1.6-kb proximal promoter.
Conflicting data have been reported on whether GHRH receptor expression is dependent upon sex. Some reports suggest that males express the receptor mRNA at much higher levels than females (36, 65) . Other studies have reported no difference between receptor expression in males and females (66, 67) . The explanation for the conflict in the literature is not clear. One possibility is that female cycle status should be taken into account, considering that the GHRH receptor is known to be regulated by estrogen (38, 68) . Expression of the GHRH receptor promoter transgene is consistently higher in males than in age-matched females, with an approximate 5-fold difference. The data indicate that sexual dimorphism of GHRH receptor expression is controlled by elements in the 1.6-kb receptor promoter. Sexually dimorphic GHRH receptor gene expression may contribute to the differing pulsatile pattern of GH release in males and females and the resulting average size difference between the sexes.
A previous study in the rat using ribonuclease protection assays has shown that expression of the endogenous GHRH receptor transcript is regulated during early postnatal development and aging.
Endogenous GHRH receptor expression is high in newborns and declines until puberty, when expression increases, before again declining throughout aging (62) . Subsequent reports have further substantiated that GHRH receptor mRNA expression dramatically decreases in the aged animal (66, 67) . In the transgenic mouse, the transgene expression pattern during postnatal development shows an increase in expression as the animals approach puberty, although transgene levels do not steadily decrease during aging, as endogenous expression levels do. The data suggest that the regulatory elements for the pubertal surge in GHRH receptor expression are contained within the 1.6-kb promoter, but other upstream elements might be involved in the decreased expression during the aging of the animal. Alternatively, regulation of GHRH receptor protein levels may differ from mRNA regulation, possibly explaining the differences reported here. Another possibility is that this aspect of regulation of the GHRH receptor gene differs between rat and mouse species.
The data show that 1.6 kb of the rGHRH receptor promoter is sufficient to target tissue-and cell-specific expression of the receptor in vivo. In addition, the data suggest that the increase in GHRH receptor expression coincident with the pubertal increase in GH levels and sex-dependent expression of the receptor are regulated by elements within this 1.6-kb proximal promoter. Having established this part of the promoter as sufficient in vivo for appropriate expression, we further examined its regulation in cell culture experiments.
We showed that the cell specificity of expression driven by the 1.6-kb promoter is mimicked in cell culture. Because coexpression of Pit-1 led to activation of this promoter reporter construct in nonpituitary Ϫ1178 to Ϫ1153 tattgattattaataccactaatgc ** ** * Ϫ1148 to Ϫ1123 ggagatgaagcatgactaatcacgt ** * Ϫ925 to Ϫ892 tgatgtcaaatgattcccagatgcagatgtggt ** ** Ϫ888 to Ϫ857 ggaagctttccacattcatgacacaaattc ** * Ϫ818 to Ϫ781 tctgtaagtggatacggtcattccgtggt *** ** Ϫ536 to Ϫ501 cagaaactttgcctaacgcatgtgagttgggggcc ** * Ϫ373 to Ϫ338 ggagccacacacatgttgaccaagtgctttaccac ** * * Ϫ348 to Ϫ313 gctttaccactgagcgacactcccagccctgcatg ** * * Ϫ81 to Ϫ46 ctgaaaacaatgggaaaacatactaagtggaacag * * ** ϩ129 to ϩ164 CTGTTCAATATTCAGCTGGGTGTCCCTCCTGTTG ** ** Each Pit-1 binding sequence and promoter location is shown, along with the mutations that affect binding, which were also examined in functional experiments. The nucleotides marked with asterisks were mutated to guanines for binding and functional assays.
HeLa cells, we focused on Pit-1 regulation of the 1.6-kb rGHRH receptor promoter with a goal of identifying functional Pit-1 binding sites. We were able to effectively narrow down specific Pit-1 binding sites to ten 25-to 35-bp regions. Only two of the 10 sites correspond to computationally predicted Pit-1 binding sites (43) , illuminating the lack of consensus for Pit-1 binding sequences. To determine whether a single or few sites contributes most to Pit-1 activation of the rGHRH receptor promoter, we examined relative binding affinities and sequence conservation to zero in on candidate regions. Combined with functional analysis of promoter 5Ј-deletion and Pit-1 binding mutation constructs, the data revealed that multiple binding regions contribute to Pit-1 activation of the rGHRH receptor promoter. Of particular importance are two well-conserved sites with high relative affinities for Pit-1, Ϫ888 to Ϫ857 and ϩ129 to ϩ164.
The required ϩ129 to ϩ164 site has previously been identified as a Pit-1 binding site that synergizes with glucocorticoid receptor to activate transcription of the Shown is a representative of three independent experiments. B, Arbitrary densitometric units were calculated for each probe using ImageQuant software. Data are representative of three independent experiments. C, Relative affinities of Pit-1 binding sites were determined by calculation of the EC 50 values for each probe, using the GraphPad Prism program (N.E., nuclear extract). A relative affinity rank is also provided, with the rank of first having the highest affinity and the rank of tenth having the lowest. Conservation of Pit-1 binding probe sequences was determined across multiple species, and the degree of conservation was translated to a rank, shown here. The rank of first is most highly conserved, and tenth is least highly conserved. rGHRH receptor promoter (54) . In addition, this site corresponds to one of the human sites identified by Iguchi et al. (44) , which contributes most to Pit-1 activation of the human GHRH receptor promoter. Interestingly, a mutation in a different human Pit-1 site, which corresponds to a region in the rat that does not bind Pit-1, has been discovered in a human familial isolated GH deficiency type IB case (45) . Our data . Pit-1 Activation of rGHRH Receptor Promoter Luciferase Reporter Deletion and Mutation Constructs A, HeLa T4 cells were transfected with 5Ј-deletion rGHRH receptor promoter constructs alone or with a cotransfected Pit-1 expression construct and analyzed for luciferase expression. Data are representative of at least three independent experiments performed in triplicate. Error bars represent the SEM. Statistical analysis was performed using a Student's t test (ns, P Ͼ 0.05; *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001). B, The fold increase in reporter activity with Pit-1 coexpression is plotted for each of the 5Ј-promoter-deletion constructs. Data represent the average of at least three independent experiments. Error bars represent the SEM. Statistical analysis was performed using a one-way ANOVA (ns, P Ͼ 0.05; *, P Ͻ 0.05; ***, P Ͻ 0.001). C, Individual mutations of the 10 Pit-1 binding sites were examined by transfection and
Fig. 10. Expression of rGHRH Receptor Promoter Luciferase Reporter Deletion and Mutation Constructs in Pituitary Cells
A, GH3 cells were transfected with 5Ј-deletion rGHRH receptor promoter constructs and analyzed for luciferase expression. Data are representative of at least three independent experiments performed in triplicate. Error bars represent the SEM. Statistical analysis was performed using a one-way ANOVA (ns, P Ͼ 0.05; *, P Ͻ 0.05; ***, P Ͻ 0.001). B, Mutation of the ϩ129 to ϩ164 Pit-1 binding site was examined by transfection and luciferase assay in GH3 cells. Data are representative of six independent experiments performed in triplicate. Error bars represent the SEM. Statistical analysis was performed using Student's t test (ns, P Ͼ 0.05; *, P Ͻ 0.05). mut, Mutation; ns, nonsignificant. luciferase assay in HeLa cells. Data are representative of at least three independent experiments performed in triplicate. Error bars represent the SEM. Statistical analysis was performed using a Student's t test (ns, P Ͼ 0.05; *, P Ͻ 0.05). D, The fold increase in reporter activity with Pit-1 coexpression is plotted for each of the 5Ј-promoter deletion constructs. Data represent the average of at least three independent experiments. Error bars represent the SEM. Statistical analysis was performed using a one-way ANOVA (ns, P Ͼ 0.05; *, P Ͻ 0.05; **, P Ͻ 0.01). Mut, Mutation; ns, nonsignificant; RLU, relative light units.
confirm that the ϩ129 to ϩ164 site is essential to Pit-1 activation of the GHRH receptor gene. Furthermore, we have identified four additional functional Pit-1 binding sites that contribute to activation of the rat promoter. Of these, the Ϫ888 to Ϫ857 site contributes most to Pit-1 activation. Interestingly, there is a predicted glucocorticoid receptor binding site within this region, suggesting that Pit-1 might synergize with GR at this site, as well.
The current study identifies the 1.6-kb promoter as sufficient for tissue-and cell-specific expression of the rGHRH receptor gene in vivo. Further analysis of the promoter shows that cell specificity of expression is maintained in cell culture. Pit-1 is an important activator of the GHRH receptor promoter, and an in-depth characterization of Pit-1 regulation of this gene reveals at least 10 short regions that specifically bind Pit-1. The identification of several Pit-1 binding sites within the promoter of a single gene is not unexpected. Multiple binding sites for Pit-1 have been identified in the promoters of other known Pit-1 targets (48, 63, 69, 70) , as well, which seems to be indicative of the importance of this factor in regulating cell-specific genes in the thyrotroph, lactotroph, and somatotroph lineages.
A report on estrogen regulation of the prolactin promoter shows a requirement for multiple Pit-1 binding sites to facilitate estrogen responsiveness (70) , which confers cell-specific expression of this gene. It is likely that the Pit-1 binding sites identified in the rGHRH receptor promoter similarly synergize with cell-specific factors to facilitate somatotroph-specific expression of the gene. Future work will focus on examining the factors that work in addition to Pit-1, or in synergy with it, to regulate the cell-specific expression of the GHRH receptor gene.
MATERIALS AND METHODS
Generation and Maintenance of Transgenic Mice
Transgenic mice were generated by the Case Western Reserve University (CWRU) transgenic facility according to the standard technique described in Ref. 71 and following protocols approved by the CWRU institutional animal care and use committee. The transgene was created by cloning the 1.6-kb GHRH receptor proximal promoter into the pA3 luciferase vector. NcoI digestion linearized the transgene, which was purified and diluted in T10E1 buffer. Transgene DNA was microinjected into the pronucleus of zygotes at 2-4 ng/l. Injected embryos were surgically transferred to the oviducts of pseudopregnant recipient females. Animals used to generate founders were F 1 hybrids of C57/Bl6 ϫ SJL. Two founder male mice were identified and used to establish two separate transgenic lines. The transgenic lines were maintained by crossing transgenic offspring to C57/Bl6 mice. Genotyping was performed on genomic DNA extracted from tail biopsies by PCR using primers to amplify the luciferase reporter (5Ј-GATTCTAAAACGGATTACCAG-3Ј and 5Ј-GTGT-TGTAACAATATCGATTC-3Ј). Mice were housed and bred in a controlled barrier facility at Northwestern University's Center of Comparative Medicine. Temperature, humidity, and photoperiod (12-h light, 12-h dark) were kept constant. Mice were fed a phytoestrogen-free diet (Harlan Teklad Global 2019 or Harlan Teklad Breeder diet 2919). All animal protocols were approved by the animal care and use committees of CWRU (Cleveland, OH) and Northwestern University (Evanston, IL), and animals were maintained in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Luciferase Assays on Pituitary Protein Extracts
Pituitary glands were removed after euthanasia by CO 2 and decapitation. Pituitaries were placed in 100 l 1ϫ Reporter Lysis Buffer (Promega Corp., Madison, WI) and homogenized using a hand-held motorized grinder. Samples were stored on ice for 15 min, cleared by centrifugation, and frozen at Ϫ80 C for at least 1 h to facilitate efficient cell lysis. Thawed samples were recentrifuged, and 25 l of the supernatant was used in a luciferase assay by injecting 100 l of Luciferase Assay Reagent (Promega Corp.) with a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA). Protein assays were performed using the Bio-Rad protein assay dye reagent (Bio-Rad Laboratories, Inc., Richmond, CA). Relative light units were normalized to protein concentration for each sample. Statistical analysis was performed using GraphPad PRISM 4.0 (GraphPad Software, Inc., San Diego, CA).
Pituitary Dispersions
Pituitaries were removed after euthanasia by CO 2 U/ml DNase II (Sigma) in HDB; filter-sterilized aliquots were stored at Ϫ20 C before use in a 15-ml conical tube by shaking at 100 rpm in a 37 C water bath for 2 h. During the last half-hour of dispersion, the cells were triturated with a siliconized Pasteur pipette. Dispersed cells were centrifuged at 1000 rpm, and the supernatant was discarded. Freshly prepared 1ϫ pancreatin (Sigma) (2.5 mg/ml in HDB) was added to the cells, and the cells were incubated at 37 C, 100 rpm for an additional 7 min. Charcoal-stripped fetal bovine serum (2 ml) (Invitrogen Life Technologies, Inc.) was added to stop the action of pancreatin, and cells were centrifuged at 1000 rpm for 10 min. Cells were washed twice with 420 l culture media (low-glucose DMEM with 10% horse serum and 2.5% fetal bovine serum with penicillin/streptomycin and fungizone). Cells were resuspended in culture media, filtered through nylon mesh, and viable cells were counted on a hemocytometer using Trypan Blue staining. Cells were plated on collagen I-coated eight-well chamber slides (BD Biosciences, San Jose, CA) at approximately 1.5 ϫ 10 5 cells per well.
Immunocytochemistry
Immunocytochemistry was performed on dispersed pituitary cells after culturing for 16-24 h at 37 C in culture media. Cells were fixed in 1% paraformaldehyde for 30 min at 4 C and permeabilized in 0.02% Triton X-100 for 5 min at room temperature, and blocking was performed by incubation in 6% BSA for 30 min at room temperature. 
Vaccinia Transfection System
HeLa T4 cells, maintained in DMEM with 4.5 g/liter glucose and L-glutamine (Mediatech, Inc., Herndon, VA) and 5% fetal bovine serum (Mediatech, Inc.), were transfected with constructs using the vaccinia virus-T7 polymerase expression system (obtained under license from Dr. Bernard Moss, National Institutes of Health, Bethesda, MD), as described elsewhere (72) . For transfection, the cells were incubated with vaccinia at a multiplicity of infection of 10 in PBS/0.1% BSA for 30 min. Cells were transfected either with a Pit-1 expression construct (a gift from Dr. Holly A. Ingraham, University of California at San Francisco) or with empty vector. Plasmid DNAs to be transfected were incubated with liposomes (73, 74) at 5 g lipid/g DNA in OptiMEM media (Life Technologies, Inc., Gaithersburg, MD) for 15-20 min at room temperature. After infection, the virus was aspirated, and the DNA/ transfectAce was added. Cells were transfected for 6 h at 37 C in 5% CO 2 and allowed to recover overnight in DMEM.
Extraction of Nuclear Proteins
After transfection, nuclear extracts were collected, as described previously (75) . HeLa cells were washed twice with cold 1ϫ PBS and scrape collected in 1 ml 1ϫ PBS with protease inhibitors (1 g/ml aprotinin, leupeptin, antipain, and pepstatin) in microcentrifuge tubes. Cells were pelleted by spinning for 5 min at 500 ϫ g at 4 C. The cell pellet was resuspended in 5ϫ volume of Buffer A [10 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonylfluoride with 1 g/ml aprotinin, leupeptin, antipain and pepstatin] and incubated on ice for 15 min, followed by homogenization by 10 strokes with a glassglass Dounce homogenizer. Samples were spun at 1,500 ϫ g for 2 min at 4 C. The nuclear pellet was resuspended in two thirds volume Buffer C (20 mM HEPES, pH 7.9; 1.5 mM MgCl 2 ; 420 mM NaCl; 0.2 mM EDTA; 25% glycerol; 0.5 mM DTT; 0.5 mM phenylmethylsulfonylfluoride with 1 g/ml aprotinin, leupeptin, antipain, and pepstatin) while constantly stirring with a micro stir bar on ice. After stirring for 30 min, samples were spun at 13,000 ϫ g for 10 min. The supernatant was aliquoted and stored at Ϫ80 C. Protein concentration was determined by Bradford Protein Assay using Bio-Rad dye reagent (BioRad Laboratories, Hercules, CA).
Western Blot Analysis
Nuclear extracts (10 g) were boiled for 5 min in sample buffer and size separated by SDS-PAGE on a 10% acrylamide gel. Proteins were transferred to a nitrocellulose membrane (BA-85; Schleicher & Schuell, Keene, NH) by electrophoresis. The membrane was blocked with 3% nonfat dry milk in PBS (blocking buffer) for 20 min at room temperature with shaking, followed by incubation with a 1:100 dilution of Pit-1 antibody (PRB-230C; Covance Laboratories, Inc., Berkeley, CA) in blocking buffer overnight at 4 C with shaking. The blot was washed twice with water and incubated with a 1:3000 dilution of secondary antibody [goat-antirabbit conjugated to horseradish peroxidase (Promega)] in blocking buffer for 90 min. The blot was washed twice with water, then in PBS/0.05% Tween for 5 min, and finally washed in five changes of water. The antibody-antigen complexes were detected by enhanced chemiluminescence (ECL-Plus kit, Amersham, Little Chalfont, Buckinghamshire, UK).
EMSAs
DNA probes for EMSAs were generated either by PCR incorporating 32 P-dCTP (GE Healthcare, Piscataway, NJ) for probes longer than 100 bp or by end labeling annealed complementary oligonucleotides in a T4 kinase reaction using 32 P-␥ATP (MP Biomedicals, Solon, OH), for shorter probes. Labeled probes were gel purified on 5-12% acrylamide/TBE (Tris-borate, EDTA) gels and eluted from the gel in 0.5 M NH 4 OAc and 1 mM EDTA. Probe eluates were spun through nylon wool, ethanol precipitated twice, and resuspended in 50 l double distilled H 2 O. Each probe (1 l) was counted on a scintillation counter, and probes were diluted for use at 1.0 ϫ 10 4 cpm per reaction. In each reaction, 5 g nuclear extract was used, unless otherwise indicated. Nuclear extracts were incubated with 1ϫ EMSA buffer (5ϫ EMSA buffer: 5 mM DTT; 5 mM MgCl 2 ; 50 mM Tris, pH 7.5), 0.2 g/l polydeoxyinosinic deoxycytidylic acid double strand (Amersham Biosciences, Piscataway, NJ), and radiolabeled probe in a final volume of 10-15 l for 20 min at room temperature. For supershift experiments, 2 l Pit-1 antibody (200 g/ml) (sc-16289; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was incubated with nuclear extract for 30 min on ice before the addition of the probes. TBE loading dye (30% glycerol/ 70% TBE with 16 mg/ml bromophenol blue and 16 mg/ml xylene cyanole) was added to each sample, and the samples were run on a 5% acrylamide/TBE gel at 4 C. Gels were exposed to Kodak X-OMAT AR film (Rochester, NY) overnight, and exposed to PhosphorImager screens (Molecular Dynamics, Inc., Sunnyvale, CA) for quantification using a STORM 860 phosphor imager (GE Healthcare) and ImageQuant 5.0 software (Molecular Dynamics).
Generation of 5-Deletion and Mutation Constructs, Transient Transfections, and Luciferase Assays
rGHRH receptor promoter 5Ј-deletion constructs were generated by PCR using 5Ј-primers with a KpnI site and a 3Ј-primer with either an NheI site (Ϫ1673, Ϫ1355, Ϫ1115) or a HindIII site (Ϫ840, Ϫ601, Ϫ396, Ϫ131) using the Ϫ1673 rGHRH receptor promoter construct as a template. Primers were generated by Integrated DNA Technologies (Coralville, IA). Primer sequences follow: Ϫ1673 5Ј, 5Ј-GCGGTACCCCATGGCCTC TGCATCAACTTCTG-3Ј; Ϫ1355 5Ј, 5Ј-GCGGTACCGGTTGTGGGAGCTCCCTACT-GCAT-3Ј; Ϫ1115 5Ј, 5Ј-GCGGTAC CGGGTGTGGCAGC-CTCTGTCCCCTTTTA-3Ј; Ϫ840 5Ј, 5Ј-GCGGTACCTG-GCACCCCCC AGCACAACAGCTCTGTAA-3Ј; Ϫ601 5Ј, 5Ј-GCGGTACCAGCCCCAGAGATCCCTCTGAG AGTCCT-3Ј; Ϫ396 5Ј, 5Ј-GCGGTACCTGTGGTGCCAGGGATTTG AAC-CTGGAGCC-3Ј; Ϫ131 5Ј, 5Ј-GCGGTACCCGTGCAGG-TATAGGAGGCCTCTCTGAG-3Ј; ϩ148 5Ј, 5Ј-GCGGTA
